19 Results for "

irreversible mutant-selective

" in MedChemExpress (MCE) Product Catalog:
Products (19)

19 Results for "irreversible mutant-selective" in MCE Product Catalog:

202
202 Publications Verification
Cat. No.: HY-15772
CAS No.: 1421373-65-0
Purity:  99.92%
Synonyms: AZD-9291; Mereletinib
Target:  

EGFR

Research Areas:  

Cancer

Osimertinib (AZD9291) is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M, respectively. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer .
loading...
    loading...
202
202 Publications Verification
Cat. No.: HY-15772A
CAS No.: 1421373-66-1
Purity:  99.97%
Synonyms: AZD-9291 mesylate; Mereletinib mesylate
Target:  

EGFR

Research Areas:  

Cancer

Osimertinib mesylate (AZD9291 mesylate) is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer .
loading...
    loading...
202
202 Publications Verification
Cat. No.: HY-79077
CAS No.: 2070014-82-1
Synonyms: AZD-9291 dimesylate; Mereletinib dimesylate
Target:  

EGFR

Research Areas:  

Cancer

Osimertinib dimesylate (AZD-9291 dimesylate) is an irreversible and mutant selective EGFR inhibitor with IC50s of 12 and 1 nM against EGFR L858R and EGFR L858R/T790M, respectively.
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-19729
CAS No.: 1448232-80-1
Synonyms: ASP8273
Target:  

EGFR

Research Areas:  

Cancer

Naquotinib (ASP8273) is an orally available, mutant-selective and irreversible EGFR inhibitor; with IC50s of 8-33 nM toward EGFR mutants and 230 nM for EGFR.
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-19803
CAS No.: 1448237-05-5
Synonyms: ASP8273 mesylate
Target:  

EGFR

Research Areas:  

Cancer

Naquotinib mesylate (ASP8273 mesylate) is an orally available, mutant-selective and irreversible EGFR inhibitor; with IC50s of 8-33 nM toward EGFR mutants and 230 nM for EGFR.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-139920
CAS No.: 2035089-28-0
Purity:  99.59%
Synonyms: SH-1028
Target:  

EGFR

Research Areas:  

Cancer

Oritinib (SH-1028), an irreversible third-generation EGFR TKI, overcomes T790M-mediated resistance in non-small cell lung cancer. Oritinib (SH-1028), a mutant-selective inhibitor of EGFR kinase activity, inhibits EGFR WT, EGFR L858R, EGFR L861Q, EGFR L858R/T790M, EGFR d746-750 and EGFR d746-750/T790M kinases, with IC50s of 18, 0.7, 4, 0.1, 1.4 and 0.89 nM, respectively .
loading...
    loading...
Cat. No.: HY-15772R
CAS No.: 1421373-65-0
Synonyms: AZD-9291 (Standard); Mereletinib (Standard)
Research Areas:  

Cancer

Osimertinib (Standard) is the analytical standard of Osimertinib. This product is intended for research and analytical applications. Osimertinib (AZD9291) is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M, respectively. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer .
loading...
    loading...
Cat. No.: HY-15772S1
CAS No.: 2254100-49-5
Synonyms: AZD-9291-13C,d3; Mereletinib-13C,d3
Osimertinib- 13C,d3 is the deuterium and 13C labeled Osimertinib. Osimertinib (AZD9291) is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M, respectively.
loading...
    loading...
Cat. No.: HY-19985
CAS No.: 1428774-45-1
Target:  

EGFR

Research Areas:  

Cancer

PF-06459988 is an orally activity, irreversible and mutant-selective inhibitor of EGFR mutant forms. PF-06459988 demonstrates high potency and specificity to the T790M-containing double mutant EGFRs. PF-06459988 can be used for the research of cancer .
loading...
    loading...
Cat. No.: HY-13897
CAS No.: 1375465-09-0
Purity:  98.42%
Target:  

EGFR

Research Areas:  

Cancer

CNX-2006 is a mutant-selective and irreversible EGFR inhibitor with an IC50 below 20 nM for EGFR T790M.
loading...
    loading...
Cat. No.: HY-15772S
CAS No.: 1638281-44-3
Purity:  99.97%
Synonyms: AZD-9291-d6; Mereletinib-d6
Osimertinib-d6 is a deuterium labeled osimertinib. Osimertinib is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer .
loading...
    loading...
Cat. No.: HY-15772AR
CAS No.: 1421373-66-1
Synonyms: AZD-9291 mesylate (Standard); Mereletinib mesylate (Standard)
Research Areas:  

Cancer

Osimertinib (mesylate) (Standard) is the analytical standard of Osimertinib (mesylate). This product is intended for research and analytical applications. Osimertinib mesylate (AZD9291 mesylate) is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer .
loading...
    loading...
Cat. No.: HY-100520
CAS No.: 1643497-70-4
Target:  

EGFR

Research Areas:  

Cancer

EGFR-IN-2 is a a noncovalent, irreversible, mutant-selective second generation EGFR inhibitor.
loading...
    loading...
Cat. No.: HY-164464
CAS No.: 1644502-33-9
Target:  

EGFR

Research Areas:  

Cancer

BPI-15086 an orally active, potent, irreversible mutant-selective inhibitor of both EGFR and T790M resistance mutations tyrosine kinase. BPI-15086 can be used for the research of non-small-cell lung cancer .
loading...
    loading...
Cat. No.: HY-174293
CAS No.: 2564638-97-5
Target:  

Drug Derivative

Research Areas:  

Cancer

Osimertinib dimer is a dimer of Osimertinib (HY-15772). Osimertinib (AZD9291) is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M, respectively. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer .
loading...
    loading...
Cat. No.: HY-19617A
CAS No.: 2227455-78-7
Target:  

EGFR

Research Areas:  

Cancer

EGFR-IN-1 hydrochloride is an orally active and irreversible L858R/T790M mutant selective EGFR inhibitor. EGFR-IN-1 hydrochloride potently inhibits Gefitinib-resistant EGFR L858R, T790M with 100-fold selectivity over wild-type EGFR. EGFR-IN-1 hydrochloride displays strong antiproliferative activity against the H1975 cells and the first line mutant HCC827 cells. Antitumor activity .
loading...
    loading...
Cat. No.: HY-79077R
CAS No.: 2070014-82-1
Synonyms: AZD-9291 dimesylate (Standard); Mereletinib dimesylate (Standard)
Research Areas:  

Cancer

Osimertinib (dimesylate) (Standard) is the analytical standard of Osimertinib (dimesylate). This product is intended for research and analytical applications. Osimertinib dimesylate (AZD-9291 dimesylate) is an irreversible and mutant selective EGFR inhibitor with IC50s of 12 and 1 nM against EGFRL858R and EGFRL858R/T790M, respectively.
loading...
    loading...
Cat. No.: HY-19617B
CAS No.: 2753348-63-7
Target:  

EGFR

Research Areas:  

Cancer

EGFR-IN-1 TFA is an orally active and irreversible L858R/T790M mutant selective EGFR inhibitor. EGFR-IN-1 TFA potently inhibits Gefitinib-resistant EGFR L858R, T790M with 100-fold selectivity over wild-type EGFR. EGFR-IN-1 TFA displays strong antiproliferative activity against the H1975 cells and the first line mutant HCC827 cells. Antitumor activity .
loading...
    loading...
Cat. No.: HY-19617
CAS No.: 1625677-63-5
Target:  

EGFR

Research Areas:  

Cancer

EGFR-IN-1 (compound 24) is an orally active and irreversible L858R/T790M mutant selective EGFR inhibitor. EGFR-IN-1 potently inhibits Gefitinib-resistant EGFR L858R, T790M with 100-fold selectivity over wild-type EGFR. EGFR-IN-1 displays strong antiproliferative activity against the H1975 cells and the first line mutant HCC827 cells. Antitumor activity .
loading...
    loading...
  • 1